Mikael Dolsten
CIK 1437590 · President R&D · last filed 2026-07-06
Mikael Dolsten is a President R&D who has filed 121 SEC Form 4 insider transactions across 7 companies since 2008. The most recent filing, for RCKT, was dated Jul 6, 2026. Across all open-market trades the lifetime net is −$31.7M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $9.2M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$9.18M
7
121
-$31.70M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| RCKT | Director | 67,082 | $3.15 | $211.6K | $0 | 1 | 2026-07-06 |
| A | Director | 5,548 | $141.08 | $782.8K | -$606.2K | 8 | 2026-06-02 |
| Apellis Pharmaceuticals, Inc. (APLS) Delisted | Director | 0 | $41.03 | $0 | $0 | 2 | 2026-05-14 |
| RCKTW | Director | 44,220 | $0.00 | $146 | $0 | 3 | 2025-07-18 |
| PFE | President R&D | 323,710 | $25.27 | $8.18M | -$31.09M | 93 | 2024-09-16 |
| KPTI | Director | — | $7.14 | — | $0 | 8 | 2021-05-21 |
| WYETH (WYE) Delisted | Sr. VP & Pres., Wyeth Research | — | — | — | $0 | 1 | 2008-06-18 |
Recent Filings
121 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-06 | RCKT | Grant (A) | +22,862 | $0 | EDGAR |
| 2026-06-02 | A | Sell (S) | −1,600 | -$216.7K | EDGAR |
| 2026-05-29 | A | Notice (144) | −1,600 | -$216.7K | EDGAR |
| 2026-05-14 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Mixed | −28,624 | $0 | EDGAR |
| 2026-03-23 | A | Grant (A) | +2,158 | $241.2K | EDGAR |
| 2026-03-03 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Grant (A) | +14,312 | $0 | EDGAR |
| 2025-12-03 | A | Sell (S) | −2,600 | -$389.5K | EDGAR |
| 2025-12-01 | A | Notice (144) | −2,600 | -$389.5K | EDGAR |
| 2025-07-18 | RCKTW | Grant (A) | +30,000 | $0 | EDGAR |
| 2025-05-23 | PFE | Notice (144) | −59,781 | -$1.38M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.